In clinical trials involving patients diagnosed with T2DM or obesity without diabetes, SGLT2 inhibitor-induced glycosuria led to a decrease in plasma glucose and insulin levels while simultaneously increasing both fasting and post-meal glucagon concentrations. Here, SLC5A2 is linked to obesity disorder.